Anticonvulsant effect of equilibrative nucleoside transporters 1 inhibitor in a mouse model of Dravet syndrome

Hippocampus. 2024 Jan;34(1):7-13. doi: 10.1002/hipo.23584. Epub 2023 Nov 6.

Abstract

There are limited therapeutic options for patients with Dravet syndrome (DS). The equilibrative nucleoside transporters 1 (ENT1) mediate both the influx and efflux of adenosine across the cell membrane exerted beneficial effects in the treatment of epilepsy. This study aimed to evaluate the anticonvulsant effect of the ENT1 inhibitor in an animal model of DS (Scn1aE1099X/+ mice). J7 (5 mg/kg) treatment was efficacious in elevating seizure threshold in Scn1aE1099X/+ mice after hyperthermia exposure. Moreover, the J7 treatment significantly reduced the frequency of spontaneous excitatory post-synaptic currents (sEPSCs, ~35% reduction) without affecting the amplitude in dentate gyrus (DG) granule cells. Pretreatment with the adenosine A1 receptor (A1R) antagonist, DPCPX, abolished the J7 effects on sEPSCs. These observations suggest that the J7 shows an anticonvulsant effect in hyperthermia-induced seizures in Scn1aE1099X/+ mice. This effect possibly acts on presynaptic A1R-mediated signaling modulation in granule cells.

Keywords: A1R; ENT1; Scn1a; febrile seizure; patch-clamp.

MeSH terms

  • Animals
  • Anticonvulsants / pharmacology
  • Anticonvulsants / therapeutic use
  • Disease Models, Animal
  • Epilepsies, Myoclonic* / drug therapy
  • Epilepsies, Myoclonic* / genetics
  • Epilepsies, Myoclonic* / metabolism
  • Epilepsy*
  • Humans
  • Mice
  • NAV1.1 Voltage-Gated Sodium Channel / genetics
  • Neurons / metabolism
  • Nucleosides / therapeutic use

Substances

  • Anticonvulsants
  • Nucleosides
  • Scn1a protein, mouse
  • NAV1.1 Voltage-Gated Sodium Channel